AU2003291689A8 - Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization - Google Patents
Stable liquid pharmaceutical formulation of antibodies that are prone to isomerizationInfo
- Publication number
- AU2003291689A8 AU2003291689A8 AU2003291689A AU2003291689A AU2003291689A8 AU 2003291689 A8 AU2003291689 A8 AU 2003291689A8 AU 2003291689 A AU2003291689 A AU 2003291689A AU 2003291689 A AU2003291689 A AU 2003291689A AU 2003291689 A8 AU2003291689 A8 AU 2003291689A8
- Authority
- AU
- Australia
- Prior art keywords
- isomerization
- prone
- antibodies
- pharmaceutical formulation
- liquid pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42298002P | 2002-10-31 | 2002-10-31 | |
US60/422,980 | 2002-10-31 | ||
PCT/US2003/034950 WO2004039337A2 (en) | 2002-10-31 | 2003-10-31 | Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2003291689A1 AU2003291689A1 (en) | 2004-05-25 |
AU2003291689A8 true AU2003291689A8 (en) | 2004-05-25 |
Family
ID=32230402
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2003291689A Abandoned AU2003291689A1 (en) | 2002-10-31 | 2003-10-31 | Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2003291689A1 (en) |
WO (1) | WO2004039337A2 (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1810832B (en) | 1998-10-23 | 2012-12-12 | 麒麟-安姆根有限公司 | Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity |
JP5053264B2 (en) | 2005-05-19 | 2012-10-17 | アムジェン インコーポレイテッド | Compositions and methods for increasing antibody stability |
JP2009502972A (en) * | 2005-07-29 | 2009-01-29 | アムジエン・インコーポレーテツド | Formulation that suppresses protein aggregation |
JO3324B1 (en) | 2006-04-21 | 2019-03-13 | Amgen Inc | Lyophilized Therapeutic Peptibody Formulations |
WO2008048430A2 (en) * | 2006-10-18 | 2008-04-24 | Amgen Inc. | Identification, quantification and conversion of succinimide in proteins |
MX2009003982A (en) | 2006-10-20 | 2009-04-27 | Amgen Inc | Stable polypeptide formulations. |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
SG187410A1 (en) | 2007-12-28 | 2013-02-28 | Baxter Int | Recombinant vwf formulations |
US11197916B2 (en) | 2007-12-28 | 2021-12-14 | Takeda Pharmaceutical Company Limited | Lyophilized recombinant VWF formulations |
BRPI0919693A2 (en) | 2008-10-21 | 2020-08-11 | Baxter Healthcare S.A | lyophilized stable pharmaceutical formulation |
BRPI0921429B1 (en) | 2008-11-07 | 2022-07-12 | Takeda Pharmaceutical Company Limited | STABLE LYOPHILIZED PHARMACEUTICAL FORMULATION, AND METHOD FOR PREPARING A STABLE LYOPHILIZED FACTOR |
DK3195880T3 (en) | 2010-05-14 | 2020-03-02 | Amgen Inc | Highly Concentrated Anti-Sclerostin Antibody Formulations |
KR102362002B1 (en) * | 2013-11-29 | 2022-02-10 | 제넨테크, 인크. | Antibody selection apparatus and methods |
CN115925961A (en) * | 2015-05-28 | 2023-04-07 | 生物辐射实验室股份有限公司 | Affinity ligands and methods relating thereto |
EP3615065A1 (en) | 2017-04-28 | 2020-03-04 | Amgen Inc. | Excipients to reduce the viscosity of antibody formulations and formulation compositions |
JP7307047B2 (en) | 2017-07-07 | 2023-07-11 | 武田薬品工業株式会社 | Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF |
EP3648787A1 (en) | 2017-07-07 | 2020-05-13 | Baxalta Incorporated | Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant vwf |
LT3681483T (en) | 2017-09-15 | 2022-09-12 | Amgen Inc. | Process for lyophilized pharmaceutical formulation of a therapeutic protein |
MX2020008219A (en) | 2018-02-08 | 2020-10-22 | Amgen Inc | Low ph pharmaceutical antibody formulation. |
US10934340B2 (en) | 2018-03-21 | 2021-03-02 | Baxalta Incorporated | Separation of VWF and VWF propeptide by chromatographic methods |
AU2019314355A1 (en) | 2018-07-31 | 2021-01-28 | Amgen Inc. | Pharmaceutical formulations of masked antibodies |
BR112021015068A2 (en) | 2019-02-01 | 2021-10-05 | Takeda Pharmaceutical Company Limited | PROPHYLATIC TREATMENT METHODS USING RECOMBINANT VWF (RVWF) |
MA55033A (en) | 2019-02-18 | 2021-12-29 | Lilly Co Eli | THERAPEUTIC ANTIBODY FORMULATION |
CN114929260A (en) | 2019-09-11 | 2022-08-19 | 武田药品工业株式会社 | Methods of treatment involving complexes of von willebrand factor and complement C1Q |
WO2021158777A1 (en) | 2020-02-04 | 2021-08-12 | Baxalta Incorporated | Treatment of menorrhagia in patients with severe von willebrand disease by administration of recombinant vwf |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE434680B (en) * | 1983-01-21 | 1984-08-06 | Karl Arne Lundblad | APPLICATION OF A SALT SOLUTION OF MONOCLONAL ANTIBODIES WITH RELATIVE HIGH SALT CONTENT IN BLOOD GROUP DETERMINATION |
US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
-
2003
- 2003-10-31 WO PCT/US2003/034950 patent/WO2004039337A2/en not_active Application Discontinuation
- 2003-10-31 AU AU2003291689A patent/AU2003291689A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2003291689A1 (en) | 2004-05-25 |
WO2004039337A2 (en) | 2004-05-13 |
WO2004039337A3 (en) | 2004-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2003291689A8 (en) | Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization | |
IL176749A0 (en) | ANTIBODIES TO MAdCAM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | |
ZA200506917B (en) | Liquid pharmaceutical formulations of palonosetron | |
IL179250A0 (en) | Stable crystal of 4-oxoquinoline compound and pharmaceutical compositions containing the same | |
IL163667A0 (en) | Novel sustained release pharmaceutical compounds to preventabuse of controlled substances | |
NO20161389A1 (en) | Antibodies that bind to human IGF-IR, hybridoma cell lines and nucleic acids, pharmaceutical composition comprising the same, use of the same for the preparation of pharmaceutical composition, process for the preparation of pharmaceutical composition, and uses thereof | |
NO20055774D0 (en) | Liquid stabilized protein formulations in coated pharmaceutical containers | |
EP1487488A4 (en) | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof | |
IL166809A0 (en) | Pharmaceutical nati-tnf-alpha antibody formulation | |
IL158802A0 (en) | Stable liquid formulations of antibodies | |
EP1660043A4 (en) | Immediate-release formulation of acid-labile pharmaceutical compositions | |
ZA200409862B (en) | Benzofused heteroaryl derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | |
PL375571A1 (en) | Squeeze-bottle of liquid medicine | |
IL173930A0 (en) | Pharmaceutical compositions containing forms of r-baclofen | |
EP1758617A4 (en) | Stable liquid and lyophilized formulation of proteins | |
IL187957A0 (en) | Liquid pharmaceutical formulations of docetaxel | |
IS6986A (en) | Liquid pharmaceutical composition | |
EP1575585A4 (en) | Pharmaceutical liquid composition containing pyridone derivative | |
ITMI20020189A0 (en) | COMPOSITION FOR PHARMACEUTICAL OR DIETARY USE TO CONTRACT HAIR LOSS | |
EP1539156B8 (en) | Liquid dosage forms of acid labile drugs | |
IL164464A0 (en) | Antagonists to mcp proteins, their preparation, pharmaceutical composition containing them, and their use | |
NO20021898L (en) | Pharmaceutical composition containing ciclesonide for application to mucosa | |
GB0328497D0 (en) | Compounds which bind to the active site of protein kinase enzymes | |
ITMI20011989A0 (en) | KIT FOR MIXING SUBSTANCES FOR THE CREATION OF COSMETIC PRODUCTS | |
IL173631A0 (en) | Crystal forms of 1-methyl carbapenem, processes for the preparation thereof and pharmaceutical compositions containing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |